Amorepacific studies Q1 development pushed by derma manufacturers and world enlargement

THE WHAT? Amorepacific Group reported first-quarter 2026 income and revenue development, supported by sturdy derma skincare efficiency and worldwide enlargement.

THE DETAILS The corporate posted income of KRW 1.227 trillion (+5.0% YoY) and working revenue of KRW 137.8 billion (+6.9% YoY). Development was pushed by derma manufacturers together with AESTURA, COSRX, ILLIYOON and IOPE, alongside enlargement in North America through Amazon and powerful efficiency in Japan from manufacturers reminiscent of LANEIGE and HERA.

Its core subsidiary, Amorepacific, delivered income development of 6.4% and working revenue development of seven.6%. Domestically, income rose 9% and working revenue surged 65%, supported by sturdy luxurious gifting and channel efficiency. Abroad income elevated 6%, with double-digit development in Western markets and APAC, although working revenue declined 18% resulting from elevated advertising funding and continued restructuring in China.

Key highlights included triple-digit development for AESTURA in North America, COSRX returning to development globally, and LANEIGE strengthening its place throughout Japan and APAC. In the meantime, some smaller subsidiaries noticed declines resulting from offline channel restructuring.

THE WHY? The outcomes replicate Amorepacific’s strategic pivot in the direction of high-growth derma skincare, world channel diversification and digital enlargement, whereas continued funding in worldwide markets and restructuring efforts affect short-term profitability.

Supply: Amorepacific Group